Abstract: A novel device, method and kit for reconstitution of a solid or semi-solid pharmaceutical composition by a negative pressure differential includes (i) a first adapter with a first connector, a first peripheral wall wherein the first adapter is coupled to the first vial by means of a first connector; (ii) a second adapter with a second connector, a second peripheral wall wherein the second adapter is coupled to the second vial by means of a second connector; (iii) a transfer port wherein the transfer port includes a first end ending in first adapter to gain access to first vial and a second end ending in second adapter to gain access to second vial; wherein the first adapters and the second adapter are joined together in vertical direction by means of horizontal wall; wherein the adapter connected to the vials by means of the ends.

Abstract: A novel device, method and kit for reconstitution of a solid or semi-solid pharmaceutical composition by a negative pressure differential includes (i) a first adapter with a first connector, a first peripheral wall wherein the first adapter is coupled to the first vial by means of a first connector; (ii) a second adapter with a second connector, a second peripheral wall wherein the second adapter is coupled to the second vial by means of a second connector; (iii) a transfer port wherein the transfer port includes a first end ending in first adapter to gain access to first vial and a second end ending in second adapter to gain access to second vial; wherein the first adapters and the second adapter are joined together in vertical direction by means of horizontal wall; wherein the adapter connected to the vials by means of the ends.

Abstract: The invention relates to a recombinant chimeric Fab antibody comprising a recombinant Fd and a recombinant chimeric light chain which binds to hepatitis B surface antigen with high affinity, generated by fusing variable region genes (VH and VL) of an anti-HBsAg mouse antibody 5S and constant region genes of human, CH1 region of human IgGI and the CL region of human kappa chain, wherein mouse VL and human CL are linked by overlap PCR to generate chimeric light chain and mouse VH and CH1 are linked by overlap PCR to generate chimeric Fd.